Navigation Links
Oramed to Raise $4,600,000 in Registered Direct Offering
Date:7/10/2013

, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange

Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Mobile: +972-54-792-4438
Office: +972-2-566-0001
Email: aviva@oramed.com



'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Oramed Pharmaceuticals to Present at the 11th National Life Science & Technology Week ILSI-BIOMED Conference; Tel Aviv, Israel, 2012
2. Oramed Pharmaceuticals Granted Core Technology Patent in New Zealand
3. Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012
4. Oramed Pharmaceuticals Completes $5.6 Million Funding to Advance Clinical Trials
5. Oramed Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com on February 7th
6. Shares of Oramed Pharmaceuticals Are Approved for Listing on the Nasdaq Capital Market
7. Oramed Pharmaceuticals to Present at the 4th Annual Drug Delivery & Formulation Summit in Berlin
8. Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
9. Oramed Submits New IND Application for Oral Insulin Trial in the US
10. Oramed Pharmaceuticals Appoints New Chief Operating Officer and VP of Business Development
11. Oramed Pharmaceuticals Chosen to Present at the 5th International Congress on Prediabetes and the Metabolic Syndrome in Vienna, Austria; April 18-20, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Corporation (Nasdaq: IRIX ) today reported financial results ... , Revenues were $11.8 million in the fourth ... 11% from $10.6 million in the 2013 fourth quarter. Revenues ... from $38.3 million in 2013. , Gross margin for ... the fourth quarter of the prior year. , Operating ...
(Date:3/5/2015)... March 5, 2015  BioPhotas, Inc., an FDA registered ... patented photo-therapeutic technologies to treat skin, muscle and joint ... Semper Fi Fund to provide BioPhotas, flagship product, the ... pain management solutions.  Commenting on the ... who used the Celluma at the Warrior Hope and ...
(Date:3/5/2015)... 5, 2015   ndd Medical Technologies , a ... employs precise ultrasound technology, announced that its EasyOne Pro® ... the San Antonio Pulmonary Fibrosis Support Group. The clinic ... fibrosis (PF), as well as those suspected of having ... a mere 12 square inches, EasyOne Pro provides accurate ...
Breaking Medicine Technology:IRIDEX Reports 2014 Fourth Quarter, Year-End Results 2IRIDEX Reports 2014 Fourth Quarter, Year-End Results 3IRIDEX Reports 2014 Fourth Quarter, Year-End Results 4IRIDEX Reports 2014 Fourth Quarter, Year-End Results 5IRIDEX Reports 2014 Fourth Quarter, Year-End Results 6IRIDEX Reports 2014 Fourth Quarter, Year-End Results 7IRIDEX Reports 2014 Fourth Quarter, Year-End Results 8BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 2BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 3ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 2ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 3
... Aethlon Medical, Inc. (OTC Bulletin Board: ... filtration devices to address infectious disease and cancer, ... entitled: " A Platform to Address Bioterrorism." ... at: http://www.aethlonmedical.com/knowledge-center/special-reports/ ...
... 2010 Northwestern Memorial Hospital is one ... will test whether operable lung cancer patients and their ... by hardwiring data systems to reduce medical error and ... trial co-sponsored by the Commission on Cancer and the ...
Cached Medicine Technology:'A Platform Technology to Address Bioterrorism' Released by Aethlon Medical, Inc. 2'A Platform Technology to Address Bioterrorism' Released by Aethlon Medical, Inc. 3'A Platform Technology to Address Bioterrorism' Released by Aethlon Medical, Inc. 4Lung Cancer Patients the Centerpiece for Northwestern Medicine Quality of Care Study 2Lung Cancer Patients the Centerpiece for Northwestern Medicine Quality of Care Study 3
(Date:3/6/2015)... March 06, 2015 US Sports Football ... Maryland camps – two non-contact specialty camps and one ... by Perfect Performance Training, located at Bowie State University ... developing position specific skills, speed and strength of football ... Salisbury University with Marvin Graves, former quarterback in the ...
(Date:3/6/2015)... Johnson & Johnson and Ethicon were ... 5, 2015 in Superior Court in the State of ... jury of 12 awarded Mrs. Perry $700,000 in actual ... an Ethicon TVT Abbrevo plastic sling for stress urinary ... also awarded $5 million in punitive damages. , According ...
(Date:3/6/2015)... Jvion, the Atlanta-based leader in ... Clostridium Difficile (C Diff) predictive use case for ... case is the latest in a broad compliment ... chronic conditions, and individual illnesses. Using the firm’s ... flags at risk individuals to help support clinician ...
(Date:3/6/2015)... NC (PRWEB) March 06, 2015 In a ... of Polish mesothelioma patients reported that shoulder pain was their ... story on its website. Click here to read it ... Warsaw analyzed the medical records of 49 mesothelioma patients ... them reported that it was shoulder pain that first prompted ...
(Date:3/6/2015)... 2015 FCPX developers have announced ... Studios. , “Pro3rd Hue is a lower 3rd pack with ... Pixel Film Studios. “Blurring the line between professional and armature, ... is a set of 30 customizable lower third presets made ... Hue, FCPX users can complement any design with a clean ...
Breaking Medicine News(10 mins):Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2Health News:New Report Reveals Shoulder Pain Could Signal Early Mesothelioma, According to Surviving Mesothelioma 2Health News:A New Plugin Entitled Pro3rd Hue was Released Today from Pixel Film Studios Exclusively for FCPX 2
... Pressure BioSciences, Inc. (Nasdaq: PBIO ) ("PBI" ... corporate activities, including (1) the receipt of a Phase ... National Institutes of Health ("NIH"), (2) a presentation by ... Public Health on the significant advantages in throughput ...
... Positive Committee Recommendation in European UnionCorporate Highlights:- ... Qutenza(TM) (formerly NGX-4010) for treatment of peripheral ... or in combination with other medicinal products ... by U.S. FDA for PHNUpcoming 2009 Milestones:- ...
... to Spot Punctures SoonerNORCROSS, Ga., March 20 Molnlycke ... and the only major surgical glove company with an ... its line this month that helps clinicians notice punctures ... two polyisoprene surgical gloves already in the line. ...
... 20 JLL Partners, a leading private equity investment ... provider of clinical development services (Nasdaq: PDGI ... tender offer by JLL PharmaNet Holdings, LLC ("Parent"), through ... of the outstanding shares of common stock of PharmaNet. ...
... an across-the-board increase in Californai Medicare supplement insurance plan premiums ... for new ways to maximize healthcare dollars and minimize expenses. ... ... March 20, 2009 -- Anthem Blue Cross implemented an across-the-board ...
... indicates that some aspects of peoples, cognitive skills such ... and detect relationships peak at about the age of ... 27. , "This research suggests that some aspects of age-related ... in their 20s and 30s," said Timothy Salthouse, a University ...
Cached Medicine News:Health News:Pressure BioSciences, Inc. Provides Corporate Update 2Health News:Pressure BioSciences, Inc. Provides Corporate Update 3Health News:Pressure BioSciences, Inc. Provides Corporate Update 4Health News:Pressure BioSciences, Inc. Provides Corporate Update 5Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 2Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 3Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 4Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 5Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 6Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 7Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 8Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 9Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 10Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 11Health News:Biogel Introduces Polyisoprene (PI) Indicator Underglove 2Health News:Biogel Introduces Polyisoprene (PI) Indicator Underglove 3Health News:Biogel Introduces Polyisoprene (PI) Indicator Underglove 4Health News:JLL Partners Announces Acceptance for Payment of Shares Tendered in PharmaNet Tender Offer and Commencement of Subsequent Offering Period 2Health News:JLL Partners Announces Acceptance for Payment of Shares Tendered in PharmaNet Tender Offer and Commencement of Subsequent Offering Period 3Health News:JLL Partners Announces Acceptance for Payment of Shares Tendered in PharmaNet Tender Offer and Commencement of Subsequent Offering Period 4Health News:JLL Partners Announces Acceptance for Payment of Shares Tendered in PharmaNet Tender Offer and Commencement of Subsequent Offering Period 5Health News:JLL Partners Announces Acceptance for Payment of Shares Tendered in PharmaNet Tender Offer and Commencement of Subsequent Offering Period 6Health News:JLL Partners Announces Acceptance for Payment of Shares Tendered in PharmaNet Tender Offer and Commencement of Subsequent Offering Period 7Health News:Seniors Seek to Reduce Healthcare Costs as Anthem Blue Cross Increases Premiums 2Health News:Cognitive decline begins in late 20s, study suggests 2
The Ahmed Glaucoma Valve has been successfully demonstrated to work in all types of glaucoma cases, particularly neovascular, congenital and uvietic glaucoma....
Ahmed Glaucoma Valve Flexible Plate ....
... a robust and durable drainage system. Preplaced ... globe. Pressure Ridge Molteno Implants have a ... tissue, acts as a Pressure sensitive biological ... implants allows the surgeon to choose the ...
... Baerveldt Glaucoma Implants feature a low implant ... reduced complications. The single-quadrant insertion is technically ... seton plate to be installed with less ... fenestrations of the Baerveldt implant were designed ...
Medicine Products: